

Extended Table 2. Clinical Characteristics of Responders

Study ID	Age	Gender	ECOG	Smoking Status	Days on Prior IO	Number of Prior Lines	Prior XRT History	PD-(L1) range (%)	LDL baseline	LDL at 6 weeks	LDL Change	Liver Mets	Histology	Most recent preceding therapy	Duration of response on anti-PCSK9 regimen
DUK2201-01	>65	Male	1	Former	<90	1	Yes	>50 (65)	<100	<50	>/=50	N	Squamous	Platinum doublet with pembrolizumab	>24 months
DUK2201-02	>65	Male	1	Former	>90	3	No	1-49 (2)	<100	<50	>/=50	N	Squamous	Gemcitabine	>24 months
DUK2201-10	>65	Male	1	Former	>90	2	No	>50 (80)	<100	<50	<50	N	Squamous	Pembrolizumab	13.5 months
DUK2201-16	<65	Female	0	Never	>90	1	No	>50 (70)	>100	>50	>/=50	N	Nonsquamous	Platinum doublet with pembrolizumab	6 months
DUK2201-21	>65	Male	1	Former	>90	3	No	1-49 (5)	<100	<50	>/=50	N	Squamous	GT103 plus Pembrolizumab	20 months